Claims for Patent: 5,976,529

Summary for Patent: 5,976,529

Title:	Methods of enzyme therapy by orally administering crosslinked enzyme crystals
Abstract:	A protein such as an enzyme or antibody is immobilized by crosslinking crystals of the protein with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. A preferred protein is an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease. Crosslinked enzyme crystals preferably retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred enzyme:Pronase.TM. ratio is 1:40. Enzyme crystals that are crosslinked may be microcrystals having a cross-section of 10.sup.-1 mm or less. Crosslinked enzyme or antibody crystals may be used in an assay, diagnostic kit or biosensor for detecting an analyte, in an extracorporeal device for altering a component of a fluid, in producing a product such as using crosslinked thermolysin crystals to produce aspartame and in separating a substance from a mixture. Enzyme therapy such as lipase therapy can be performed by administering orally crosslinked lipase crystals.
Inventor(s):	Navia; Manuel A. (Lexington, MA), St. Clair; Nancy L. (Charlestown, MA)
Assignee:	Vertex Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	08/477,109
Patent Claims:	1. A method for carrying out enzyme therapy in an individual, comprising the step of administering orally to said individual an enzyme crystal crosslinked with a multifunctional crosslinking agent, said crosslinked enzyme crystal having resistance to exogenous proteolysis, such that said crosslinked enzyme crystal retains at least 91% of its initial activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme that is crystallized to form said enzyme crystal that is crosslinked to lose at least 94% of its initial activity under the same conditions. 2. The method according to claim 1, wherein said enzyme is a hydrolase. 3. The method according to claim 2, wherein said hydrolase is selected from the group consisting of thermolysin, elastase, asparaginase, lysozyme and urease. 4. The method according to claim 2, wherein said hydrolase is an esterase. 5. The method according to claim 1, wherein said crystal is a microcrystal. 6. The method according to claim 5, wherein said microcrystal has a cross-section of 10.sup.-4 or less. 7. The method according to claim 1, wherein said crystal is in lyophilized form. 8. A method for carrying out lipase therapy in an individual, comprising the step of administering orally to said individual a lipase crystal crosslinked with a multifunctional crosslinking agent, said crosslinked lipase crystal having resistance to exogenous proteolysis, such that said crosslinked lipase crystal retains at least 91% of its initial activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the lipase that is crystallized to form said lipase crystal that is crosslinked to lose at least 94% of its initial activity under the same conditions.

Details for Patent 5,976,529

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2016-11-02